怀孕期高血糖症:结合方式的结果和诊断准确性
Jaishil Manga1, Natalie Odell2, Lungile Khambule3
1Charlotte Maxeke Johannesburg Academic Hospital, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Clinical medicine (London, England)
|August 7, 2025
概括
妊娠期糖尿病 (GDM) 和其他妊娠期高血糖性疾病在南非正在增加. 使用HbA1c和禁食血葡萄糖的综合诊断方法对GDM查有希望.
科学领域:
- 内分泌学 在内分泌学.
- 产科 产科 产科 产科 产科
- 公共卫生 公共卫生
背景情况:
- 怀孕期间糖尿病 (DM) 的全球流行率不断上升.
- 在南非,关于妊娠糖尿病 (GDM) 的数据有限.
- 妊娠中首次检测到的高糖血症 (HFDP) 的发病率越来越高.
研究的目的:
- 分析南非HFDP妇女的血糖特征和怀孕结果.
- 为了确定GDM的风险因素.
- 为了评估结合HbA1c和空腹血葡萄糖 (FPG) 对GDM的诊断准确性.
- 评估GDM妇女的产后结果和随访率.
主要方法:
- 对298名妊娠前DM和HFDP妇女的回顾性分析 (2019年8月 - 2021年1月).
- 过血糖性疾病的分类:GDM,2型DM (T2DM),明显DM,1型DM (T1DM).
- 风险因素的评估,糖化血红蛋白 (HbA1c),FPG和产后口服葡萄糖耐受性测试 (OGTT) 的结果.
- 使用曲线下的面积 (AUC) 计算诊断准确度.
主要成果:
- GDM是最常见的HFDP诊断 (39.6%),其次是T2DM (29.2%),明显的DM (22.1%),以及T1DM (9.1%).
- 显著的GDM风险因素包括家族病史,肥胖,不良的产科病史和以前的宏观症.
- 在HbA1c≥5.75%和FPG5.1-6.9mmol/L的组合下,GDM诊断的高精度 (AUC=0.93) 得到了证明.
- 在产后,21%的GDM病例进展为DM,而53%的患者患有葡萄糖耐受性损害 (IGT).
- 只有48%的GDM患者接受了分娩后的随访,这表明随访挑战的重大损失.
结论:
- 在南非,HFDP越来越令人担忧,产后DM发展的风险很大.
- 结合HbA1c和FPG查为改善GDM诊断提供了一个有希望的方法,特别是在资源有限的环境中.
- 改善产后随访对于减轻GDM妇女的长期并发症至关重要.
- 需要进一步的研究来验证这些诊断和预后发现.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
Diabetes: Symptoms, Diagnosis, and Complications
694
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
694
Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263


